EyePoint Pharmaceuticals appoints Karen Zaderej to Board of Directors

EyePoint, Inc.

Karen Zaderej appointed to Board effective July 11, 2022, expanding board to eight members.
She will serve on the Audit Committee; receives $45k annual retainer plus $10k for committee service.
Granted 6,000 RSUs and option for 22,000 shares vesting over three years, exercise price at grant date closing price.
Zaderej is President/CEO/Chair of AxoGen, bringing 35+ years biopharma and medical device experience.
Company expects her insight to advance lead pipeline asset EYP-1901 for wet AMD.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karen Zaderej

Director

EYPT · EyePoint, Inc.

Effective: 2022-07-11
Filed: July 14, 2022, 7:59 PM ET

increased the size of the Board to eight members and appointed Karen Zaderej to fill the vacancy on the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen Zaderej was appointed as Director at EyePoint, Inc..

Action: appointed
Role: Director

Exact text from the filing

increased the size of the Board to eight members and appointed Karen Zaderej to fill the vacancy on the Board, effective immediately.

View on SEC.gov

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-012679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.